NCT01610687已完成3 期
A Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 137
- 试验地点
- 1
- 主要终点
- Incidence of Adverse Events as a Measure of Patient Safety
研究概览
简要总结
An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.
详细描述
Patients who participated in the placebo controlled phase of this study and opted to continue receiving open label GW-1000-02 entered the follow-on extension of the study and completed symptom assessments to determine whether they were continuing to receive clinical benefit from GW-1000-02.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged at least 18 years.
- •Multiple Sclerosis of any type.
- •Stable Multiple Sclerosis symptomatology during the four weeks before study entry.
- •Symptoms of the required severity (>50 mm on a 100 mm Visual Analogue Scale severity scale) in least one of the specified impairment categories; spasticity, muscle spasms, disturbed bladder control, neuropathic pain, limb tremor.
- •A stable medication regime during the four weeks before study entry.
- •Willing to abstain from cannabis or cannabinoids for at least seven days before study entry, and during the study.
- •Agreed either to use effective contraception during the study and for three months thereafter, or had been surgically sterilised or, if female, were post-menopausal.
- •Clinically acceptable laboratory results for pre-study screening.
- •Willing and able to undertake and comply with all study requirements.
- •Willing and able to read, consider and understand the subject information and consent form and give written informed consent. Subjects unable to read or to sign the document procedures were treated as detailed in the Declaration of Helsinki.
- •Willing for their general practitioner, and consultant if appropriate, to be informed of study participation.
- •Willing for their name to be notified to Home Office for participation in the study.
排除标准
- •Known or strongly suspected to be abusing drugs, including alcohol.
- •Not prepared to abstain from cannabis or cannabinoids during the study.
- •Current or past addiction to cannabis.
- •Known or suspected to have had an adverse reaction to cannabinoids causing psychosis or other severe psychiatric illness.
- •History of any type of schizophrenia, any other psychotic illness, or other significant psychiatric illness or personality disorder other than depression associated with chronic illness.
- •Received any drug containing levodopa (Sinemet®, Sinemet plus®, Levodopa®, L-dopa®, Madopar®, Benserazide®).
- •Serious cardiovascular disorder including angina, uncontrolled hypertension, or an uncontrolled symptomatic cardiac arrhythmia.
- •Significant renal or hepatic impairment as shown in medical history or indicated by laboratory results.
- •History of epilepsy.
- •Terminal illness or other condition in which placebo medication would be inappropriate.
- •Pregnant, lactating or at risk of pregnancy.
- •Participated in any other clinical research study during the 12 weeks before study entry.
- •Planned hospital admission between study entry and Visit
- •Planned travel outside the UK between study entry and Visit 6.
研究组 & 干预措施
GW-1000-02
Experimental
Active treatment
干预措施: GW-1000-02 (Drug)
结局指标
主要结局
Incidence of Adverse Events as a Measure of Patient Safety
时间窗: up to1206 days
The number of patients who experienced an adverse event during the course of this extension study is presented
次要结局
- Change From Baseline in the Mean Pain 100 mm Visual Analogue Scale Score at Week 18(week 18)
- Change From Baseline in the Mean Spasticity 100 mm Visual Analogue Scale Score at Week 18(week 18)
- Mean Number of Sprays of Study Medication Taken During the Last 6 Days of Treatment(up to 1206 days)
- Change From Baseline in Mean Intoxication 100 mm Visual Analogue Scale Scores at Week 18.(18 weeks)
- Investigator Assessed Global Severity Score at Week 18(week 18)
- Change From Baseline in the Mean Bladder Problems 100 mm Visual Analogue Scale Score at Week 18(18 weeks)
- Change From Baseline in the Mean Tremor 100 mm Visual Analogue Scale Score at Week 18(week 18)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisMultiple SclerosisNCT00662649Novartis920
已完成
2 期
A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the KneeOsteoarthritisNCT00565812Pfizer1,457
终止
2 期
Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)Facioscapulohumeral Muscular Dystrophy (FSHD)NCT04264442Fulcrum Therapeutics76
已完成
2 期
Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)Depressive Disorder, MajorNCT00413023GlaxoSmithKline348
终止
2 期
GW873140 In Combination With Combivir In HIV Infected SubjectsInfection, Human Immunodeficiency Virus IHIV InfectionNCT00104429ViiV Healthcare125